Company Overview : Amgen Inc., (AMGN) a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases.
Prognosis : The stock has been dead money for almost a year while the market has run up 25% over the same time period. As the market has rotated to more defensive sectors over the last few weeks from high beta stocks, I see AMGN significantly outperforming
Complete Story »
Joanna Krupa Ashley Olsen Danneel Harris Veronika Vaeková Eve
No comments:
Post a Comment